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Abstract 
 
Traumatic Brain Injury is responsible for 30% of trauma related death and over 2.8 million visits 
to the emergency room, hospitalizations, and deaths in 2010. Many survivors are left with 
cognitive and motor deficits while others are left in a persistent vegetative state. Current 
treatments have shown advancement over the past decade however TBI rates continue to rise 
across the country. Recently stem cells have been tested and shown to have efficacy in many 
diseases and genetic disorders. TBI clinical trials are moving into human trials and show promise 
in both the acute and sub-acute time period. Research reports improvements in cognitive and 
motor function after injection with Mesenchymal stem cells. These cells are harvested from bone 
marrow and umbilical cord blood instead of fetal embryos. With the ability to differentiate in to 
specialized cells they have the ability to repair and renew damaged tissue. Limitations in recently 
published clinical trials show the need for more research in an exciting and rapidly expanding 
field. 
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Introduction 
Traumatic brain injury (TBI) accounted for 2.8 million emergency room visits in 2013 across the 
United States.1 Of those that experience TBI and survive, many are left with lifelong disabilities 
that result in major socioeconomic burden. In 2000, the economic impact of TBI in the United 
States was estimated to be $9.2 billion in lifetime medical costs and $51.2 billion in productivity 
losses.3 
 
Survivors of TBI are often left disabled, with long-term side effects from the initial injury. The 
negative impact on patients is substantial and seen in every aspect of their lives. They often 
experience cognitive, psychiatric, physical, emotional, and behavioral changes.1 Moderate to 
severe TBI can be devastating to patients. 50% of survivors die during the first five years after 
injury and 57% of the remaining patients will be moderately to severely disabled indefinitely.1 
 
Research exploring the potential utilization of stem cell for any number of medical conditions is 
both controversial and exciting. While there have been several recent trials involving the 
treatment of TBI in rats with stem cells there are few studies involving human patients. As 
research grows and new evidence emerges there has been increasing interest in the possibility 
that human neurons can be regenerated or produced by stem cell therapies.  
 
This paper sets out to address the clinical question: Can Mesenchymal stem cell implantation in 
patients who have suffered traumatic brain injuries regenerate or renew neuronal cells to improve 
cognitive and physical outcomes? 
Pathophysiology of TBI 
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TBI is most commonly divided into stages in order to direct treatment; primary and secondary. 
Primary TBI is a result of external mechanical forces being transferred to intracranial contents.1 
These external mechanical forces are most commonly the result of direct impact, rapid 
acceleration or deceleration, a penetrating injury, or blast waves.1 What results from these initial 
blows can be devastating. Hematomas, contusions, and shearing forces leading to diffuse axonal 
injury all occur in this primary stage of brain injury. Loss of function, coma, and even death are 
common in the first few hours of a severe brain injury.1 In motor vehicle collisions, focal 
cerebral contusions are the most commonly seen in the frontal and temporal areas from the 
extreme acceleration/deceleration caused by the impact.1 It is during this stage that physical 
damage is inflicted on neurons, glial cells, nerve fibers, and the blood brain barrier.2 
Following the initial insult, disruption in the BBB can lead to passage of immune cells into the 
central nervous system.2 The BBB stands between the brain extracellular fluid and the circulating 
peripheral blood keeping toxins at bay and regulating ion concentrations.2 Disruption in this 
system draws Astrocytes to the area creating a “glial scar” that creates a type of barricade 
keeping macrophages from the site of injury. Macrophages are cells that are important in the 
removal of damaged myelin.2 Without an influx of macrophages to the injured area the brain’s 
ability to recover is hindered.2 This so called “glial scar” is an important factor in protecting 
viable neurons in the surrounding area from damage occurring from the disruption of the BBB.2 
While preventing astrocytes from forming this scar would help macrophages enter the area to 
clear debris and aid in recovery, it could possibly open the door to more neuronal cell damage. 
The astrocytes also secrete essential metabolites to neurons that encourage neuronal survival.2 
One possible way stem cell treatments could improve outcomes in TBI is to immediately repair 
the BBB, preventing the need for astrocytes to form scars.  
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Secondary TBI is what occurs following the primary insult; it is best described as a cascade of 
molecular injuries that leads to neuronal cell death.4 This path of destruction leads to 
neurotransmitter-mediated excitotoxicity causing glutamate, free-radical injury to cell 
membranes, electrolyte imbalances, mitochondrial dysfunction, inflammatory responses, 
apoptosis, secondary ischemia from vasospasm, focal microvascular occlusion, and vascular 
injury.1 The secondary insults that occur during this process are what medical experts are 
working to alleviate with treatments during the acute setting.  
 
These pathological changes in the brain can lead to neurological deficits ranging from mild to 
severe. Symptoms of TBI are vast and associated with the amount and location of the neuronal 
damage. Patients often report nausea, vomiting, vertigo, photophobia, fatigue, and visual 
disturbances.16 Headaches are the most commonly reported symptom associated with mild TBI.14 
They can also suffer from psychological symptoms including irritability, anxiety, depression, and 
sleep disturbances.16 Cognitive impairments can include slowed or difficulty thinking, loss of 
memory, and disrupted thought patterns among others. 16 Speech and language can be affected as 
well.6 Expressive and receptive aphasia problems combined with problems reading and writing 
can lead to significant impairment in independence. Patients often lose hearing, smell, taste, and 
often report changes in vision.6 Paralysis and spasticity are two other devastating symptoms that 
can lead to placement in long-term facilities when patients are unable to care for themselves.  
While some patients survive severe TBI with only moderate sequalae there are others that remain 
in a vegetative state for the remainder of their lives. Caring for the patient falls to family and 
society, creating a challenge mentally, physically, and financially.  
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Epidemiology of TBI 
The Centers for Disease Control reports that 538.2 out of 100,000 people experienced a TBI in 
the United States in 2003.1 That number rose drastically in 2010 to an alarming 823.7 per 
100,000.17 Injuries resulting in TBI or combined with TBI were responsible for 56,000 deaths 
and 30% of injury related mortality.14  
 
The entire population is at risk of suffering from TBI during their lifetime. However, there are 
subsets of the population that are at higher risk for occurrence. Those at highest risk overall 
include the very young (0-4) and elderly (75+), many of which have suffered falls.14 The 
countries aging population has seen a 17.9% increase in falls resulting in TBI.17 These 
individuals are at a much higher risk of TBI sequelae and face long recovery times. Their 
likelihood of comorbidities, anti-coagulant use, and increased hospitalization are all likely 
factors in the increased incidence of mortality among these patients.17  
 
Falls are the leading cause of TBI-related emergency room visits in pediatric patients (0-4 years) 
but the leading cause of TBI mortality in this population is due to assault/homicide (42.9%), 
blunt trauma to the head, or violent shaking.17 Of those that survive, pediatric patients, for the 
most part, have the benefit of their youth to aid in their recovery. Sports related injury accounts 
for 21% of TBI in the adolescent population.25 While patients under 16 have the greatest chance 
of survival after the initial traumatic injury they also have the highest percentage of deficits.7 
Long term neurologic damage can lead to delayed development and missed milestones resulting 
in lifelong challenges for the child.17 With decades of their lives remaining they become 
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dependent on family members or facilities for full time care costing millions of dollars. 29% 
more males were involved in TBI-related medical care or died from their injuries in 2010 than 
females.1 Lower socioeconomic status, substance abuse, and underlying psychiatric disorder are 
all risk factors for TBI.1 
 
In 2013 motor vehicle crashes (MVC) were the leading cause of TBI-related death in 5-24 years 
of age, while intentional self-harm was number one for individuals 25-64 years of age.1 
Fortunately, for individuals 45 years of age, TBI related mortality is declining, in large part due 
to advances in motor vehicle safety, updated treatment guidelines, and increased access to 
healthcare. However, with the number of TBI related deaths decreasing every year the number of 
survivors with TBI related disabilities in this population are rising.17 
 
There are other subsets of the population that are more likely to suffer from TBI. The United 
States involvement in Middle Eastern conflict has given rise to a disproportionate increase in 
TBI in military personal verses their civilian counterpart. Over the past decade an increasing 
number of military related TBIs have been reported. An estimated 15.2% to 22.8% of service 
members return home from war with mild TBI (mTBI); an estimated 320,000 military 
personnel.12 These injuries can often go undetected, showing up months or years later as anxiety, 
sleep disturbance, forgetfulness, headaches, poor concentration, pain, psychological distress, and 
cognitive deficits in areas of executive functioning.12 Service members suffering from mTBI are 
also more likely to have persisting symptoms at the 3 month mark. It is not fully understood why 
20%-48% of these patients continue to experience symptoms while only 3%-5% of their civilian 
counterparts suffer any long-term mTBI related symptoms.13 Researchers theorize that 
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underlying co-existing mental health conditions could be to blame for the disparity.13 
 
It is estimated that 1-2% of the United States population has a long-term disability secondary to 
the brain injury.1 That is 3.2 to 5.3 million Americans suffering every day with life altering 
disabilities and the numbers continue to grow. There is also a substantial economic toll on 
society; an estimated $76.5 billion dollars was spent on moderate to severe TBI-related medical 
costs in 2010 alone.16  These symptoms can be life-long, affecting not only their daily lives but 
also shortening overall life expectancy rates by 9 years.1 They are also at increased risk for 
seizures, accidental drug poisoning, and infections are 9 times more likely.1 
 
Current Treatment 
Primary Phase Management 
Standard of care for traumatic brain injuries includes immediate attention to oxygen saturation 
and blood pressure in the pre-hospital setting. Patients are closely monitored with provision of 
early interventions such as supplemental oxygen or intravenous fluids in order to ensure 
adequate oxygenation to the brain and perfusion to vital organs.4 
 
The Glasgow coma scale (GCS) is used to direct care and aid in making decisions regarding 
treatment of TBI patients. table 1 The scale can be utilized to predict mortality rates and prognosis. 
TBI is rated on this scale by mild disability given 13-15 points, Moderate disability (9-12), 
Severe disability (3-8), and Vegetative state.16 Patients with Glasgow coma scales of <8 are 
immediately intubated at the scene and are given isotonic crystalloid fluids. 
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Table one –Uptodate  
In the acute evaluation and management of TBI, patients are monitored for stability of vital 
organs. They undergo evaluation by CT imaging, and are treated with neurosurgical procedures, 
such as evacuation of hematoma, if indicated. Intracranial pressure is also monitored; if an 
increase over 20 mmHg is detected, cerebral spinal fluid (CSF) drainage is initiated.4 
Hyperventilation of patients in an induced coma is also used to decrease intracranial pressure in 
the days following injury.1 Other treatment options include sedation, antiepileptic drugs, glucose 
management, and various pharmacologic agents. Medical professionals are in disagreement over 
many of the available treatment options for TBI however the current mainstay is the treatment of 
hypoxemia and hypotension.5 Advances have been made but there is not a huge body of evidence 
to strongly suggest that most of these treatment options have significant effect on outcomes.  
Secondary Phase Management 
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The Secondary phase of TBI can prove the most challenging for survivors. The weeks, months, 
and years following a brain injury can be devastating to an individual and their families. Patients 
participate in many different medical therapies to improve cognitive and physical function. 
Occupational and Physical therapists work with patients to improve function in every day tasks 
and gain independence. Speech Language Pathologists work to rehabilitate speech patterns and 
the ability to communicate. Psychotherapy is also important for both the patient and their 
caregivers in order to educate and support their overall well-being.14 Medications are used in this 
phase to treat symptoms commonly associated with TBI. Depakote, NSAIDS, and Triptans are 
prescribed for headaches, SSRI’s for depression, and anticonvulsants for seizures, as well as a 
myriad of other pharmacologic treatments to reduce irritability, agitation, and cognitive loss 
commonly experienced.14 
 
Stem Cell Research and Applications 
Stem cells are no longer a far-off, futuristic idea set aside for future generations to explore. In 
fact, they are already being studied in many areas of medicine today. In 1981 researchers were 
able to extract the first embryonic stem cells from mouse embryos. This research paved the way 
for researchers to extract and culture the first human embryonic stem cells in 1998.23 Stem cells 
were first discovered in the brain in the 1960’s but was not widely accepted until the 1990’s 
when published research showed proof of both the existence of stem cells within the brain and 
their ability to differentiate into astrocytes, oligodendrytes, and nerve cells.23  
 
Stem cells are cells that have the ability for self-differentiation and self-renewal.16  
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They are undifferentiated by definition but once stimulated are able to differentiate into a 
multitude of cells including neurons, cardiac, and muscle cells.16 As these cells divide they 
become either replicas of themselves, undifferentiated stem cells or they become a specialized 
cell that will become part of the body’s tissue.16 Research is being done determine how these 
cells decide what to become and the exact moment they are stimulated to do so. With this 
knowledge stem cells could be directed to an area within the body and stimulated to regenerate 
or repair specific organs or cells. At the moment it remains unclear the mechanism that begins 
each individual cell’s journey to proliferation and what directs the path to an end product. 
Researchers have theorized that stem cells may produce soluble factors that regulate the trauma 
such as cytokines, mitochondria, and growth factors by protecting cells and reducing 
inflammation.21 Stem cells may also regulate brain injury by replacing damaged cells to repoair 
tissue or stimulating other cells to repair the damaged area.21 
 
Researchers are currently studying new ways to use stem cells in diseases such as Parkinson’s, 
Multiple Sclerosis, Autism, and diabetes. The clinical question at hand, however, explores the 
use of stem cells as a therapy for TBI. 
 
One of the major controversies surrounding the medical use of stem cells is origin. Concerns of 
morality have been raised by the public in the acquisition and use of embryonic stem cells from 
an unborn fetus. Some have concerns born out of religious beliefs while others fear an increase 
in aborted fetuses. These people have raised the question- “How far is too far?” when it comes to 
acquiring these life changing and saving cells. What many do not understand is that stem cells 
are acquired through many different avenues. Human umbilical cord-derived mesenchymal stem 
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cells (hUC-MSCs) are isolated from discarded extra-embryonic tissue after birth.11 Previously it 
was believed that the only source of coveted mesenchymal stem cells were unborn fetuses. 
However further research has shown these cells exist in abundance in both the umbilical cord 
and placenta.9 The cells are readily available and the process is painless to the mother and fetus.9 
Of special interest to TBI, these cells have shown the ability to differentiate into neurons, 
astrocytes, and oligodendrocytes among others that consist of three germ layers.9 These same 
stem cells are being used in treatments for neuromylitis optica10 Bone Marrow mesenchymal 
stem cells (BMMSC) are being harvested from patients and injected back to study their ability to 
differentiate into other cells like neurons.8 In the past it was believe that adult stem cells could 
only differentiate into the organ they originated in however new and exciting research is working 
to disprove this theory. Many studies are taking autologous BMMSCs and injecting them back 
into the site of injury in hopes that they will differentiate in to the cell type that has suffered 
damage.8 They have the potential to reverse the damage in TBI by differentiating into neurons 
and regenerating function.   
 
Methods 
To answer the clinical question PubMed, EMBASE, and Google Scholar were queried with the 
following search terms; “Neuronal stem cells”, “Stem Cells AND Central Nervous System”, 
“Stem Cell AND Traumatic Brain Injury”, “Stem Cell therapy AND injection”, “Traumatic 
brain injury AND human neurons”, and “Stem Cell regeneration”. A search on 
Clinicaltrials.gov with the terms “traumatic brain injury”, “TBI AND Stem cells”, and “Stem 
Cells” was conducted as well. Background and supporting information were obtained through a 
literature search on Google Scholar, Pubmed, and UptoDate using the search terms “Traumatic 
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Brain Injury Pathophysiology”, “Stem Cells”, “Military TBI”, “Epidemiology in TBI” and 
“Traumatic Brain Injury”.  
 
Included in this paper were patient populations with mild to severe traumatic brain injury 
resulting from physical trauma, human subjects, studies within the last 10 years, English 
language, and studies that used with Mescenchymal stem cells only. Animal and other laboratory 
vectors were excluded as well as studies involving patient groups with serious co-morbidities, 
cancer, or previous TBI.  
 
The Cochrane review was used in the evaluation of each study in order to determine the validity 
of results.  
 
Results 
The search strategy yielded 600 studies, of those, 3 met inclusion criteria. Each will be 
overviewed here and are outlined in table 2.  
 
Wang et al. studied the use of umbilical cord Mesenchymal stem cells in patients with sequelae 
of traumatic brain injury. Researchers conducted a randomized, single blinded controlled clinical 
study. To be included in the study patients had to consent to treatment, could not undergo other 
treatments or surgeries three months prior to or during the study, have diagnosis of TBI with 
sequelae based on clinical manifestations as well as head CTs and MRIs, and have some degree 
of central nervous system dysfunction. Patients were excluded if they presented with signs of 
intracranial infection, hydrocephalus, skull defects (excluding crainoplasty), intractable epilepsy, 
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inherited metabolic diseases of the CNS, allergies, autoimmune diseases, history of tumors or 
blood disease, positive serologic AIDS, hepatitis, or syphilis, or showed dysfunction of vital 
organs. 40 patients were recruited for the study.  Differences in age, gender, and severity of 
injury were not statistically significant. 20 patients were given 4 treatments with umbilical stem 
cells injected via lumbar puncture while 20 patients were in the control group. All 40 patients 
were present at the conclusion of the study. Patients were given a function independence 
measurement test that tested an 18 item rating scale that assessed self-care, bowel and bladder 
management, mobility, communication, cognition, and psychosocial adjustment. Patients in both 
groups were evaluated both at baseline and 6 months after treatment. The patients who received 
umbilical stem cells had statistically significant improvement in almost all areas tested. Upper 
extremity (P<.001), lower extremity (P0.05), sensation (P<0.05), balance (P<.001), and total 
FMA score (P<0.001) were all improved 6 months after treatment while the control group did 
not show statistically significant improvement in any of the categories. Neurological 
improvements were also seen in self-care, mobility, locomotion, and communication in the stem 
cell group at the six month evaluation (P<.05). Improvements in sphincter tone and social 
cognition were slight but not significant. The control group did not experience any significant 
improvement in any of the functional groups tested.  In all groups except sphincter control, 
communication, and social cognition there were statistically significant improvements seen in the 
stem cell patient group when compared with the control. 
 
Tian et al.- conducted a non-random, open-labeled, interventional cohort with 166 patients that 
were at least one year out from initial injury. 97 patients received stem cell injection, 24 of which 
were in a persistent vegetative state (PVS) and 73 experienced motor activity disturbances. Bone 
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marrow mesenchymal stem cells were harvested and injected via lumbar puncture. Those in PVS 
showed improvement with consciousness (P=.024). Those with motor disturbances had 
improvments in motor function (P.025) and both groups combined improved by 39.2% overall. 
Patient age and time from injury to therapy were statistically significant (P<.05) but the number 
of stem cell injections did not have a significant effect. Limitations are listed in table 2.   
 
Cox et al. conducted an open label, non-randomized, single center clinical trial to further 
investigate the treatment of severe TBI using bone marrow derived mononuclear stem cells 
(BMMNC). Patients were screened in the emergency room and admitted to the trial if between 
the ages of 18 and 55 years, had a post-resuscitation GCS score of 5-8, less than 24 hours from 
initial injury, and English speaking. To ensure patients did not already suffer from irreversible 
brain injury patients were excluded if there were any known pre-existing serious medical co-
morbidity or psychiatric disorder, seizure disorder, or any previous moderate to severe TBI. 
Patients were also excluded if they were thermodynamically unstable at time of consent, suffered 
open pelvic fracture, spinal cord injury, opening intracranial pressure >40 mmHg, had evidence 
of hypoxic-ischemic insult, uncorrected coagulopathy, greater than a grade III solid or hollow 
visceral injury of the abdomen or pelvis as rated by the American Association for the Surgery of 
Trauma, pregnancy, weight >300 lbs (MRI limitations), concurrent participation in an 
interventional study, and unwillingness to return for follow up visits.  
The study consisted of 25 patients between the ages of 18 and 55 years. BMMNCs were 
harvested from patient’s superior iliac crest 36 hours after presentation, filtered and infused back 
through an IV 8 hours later. Patients were separated into four arms of treatment that differed in 
amount of stem cells placed. Stem cell dosage  in three arms of treatment were 6 x 106 BMMNC/kg 
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(low), 9 x 106 BMMNC/kg (medium), 12 x 106 BMMNC/kg(high) while the control group did not receive 
any stem cells. Blood pressure, heart rate, oxygen saturation, and intracranial pressure were 
measured at timed intervals until the 12 hour mark in all treatment arms. These measures were 
also observed and recorded post stem cell harvest to evaluate safety of the procedure. MRI was 
performed at 1 and 6 months to follow changes in neuroinflammation in patient’s Corpus 
callosum and corticospinal tract. In patients that received stem cell treatment white matter was 
preserved when compared with control as well as Supratentorial volume. These patients also 
scored higher in neurocognitive function tests. 
 
Table 2. Stem Cell Therapy Trial Summary 
Study Measurements and 
Treatment 
Results Limitations Conclusions 
Umbilical cord 
mesenchymal stem 
cell transplantation 
significantly 
improves 
neurological function 
in patients with 
sequelae of 
traumatic brain 
injury; A 
randomized, single 
blinded control trial. 
Wang et al.(2013) 
 
•  Sample size: 40  
•  Control compared with 
mesenchymal stem cell 
injection via lumbar 
puncture 4x over 5-7 
days.. 
•  Motor and neurological 
scores recorded using 
FMA and FIM at baseline 
and 6 month follow up. 
•  Upper extremity (P<.
001), lower extremity 
(P0.05), sensation 
(P<0.05), balance (P<.
001), and total FMA 
score (P<0.001)  
•  Neurological 
improvements seen in 
self-care, mobility, 
locomotion, 
communication in the 
treatment group at the 6 
month evaluation (P<.
05).  
•  Patients bias- lumbar 
puncture with stem cells no 
treatment. 
•  Small study size. 
•  Injury heterogeneity  
•  Wide range of patient 
baseline. 
•  Evidence from this trial 
suggests treatment 
with Mesenchymal 
stem cells may reduce 
neurological and motor 
sequelae years after 
injury. 
•  Need for more RCTs 
with larger patient 
population. 
Autologous Bone 
Marrow 
Mesenchymal Stem 
Cell Therapy in the 
Sub-acute Stage of 
Traumatic Brain 
Injury by Lumbar 
Punctures. A non-
random, open-
labeled, 
interventional cohort 
study. Tian, C. et al.
(2013)  
•  Sample Size- 166 
•   97 patients received 
stem cell injection. 24 in 
persistent vegetative 
state (PVS) and 73 
patients with disturbance 
motor activities. 
•  Autologous bone marrow 
via lumbar puncture 
injection. 
•  PVS improved when 
compared with non-
treatment group. 
•  39.2% improved 
overall(P=.007),  
improved consciousness 
(P=.024), improved 
motor function (P=.025) 
•  Age and time to therapy 
( P<.05) while number of 
injections was not 
significant. 
•  Patient and family bias due 
to open label. 
•  Potential observer bias. 
•  Disproportionate study 
arms.  
•  Injury heterogeneity. 
•  Unclear measures tested.  
•  Significant results could be 
due to sampling error. 
•  Evidence suggests 
safety of injection. 
•  More studies 
conducted to prove 
efficacy.  
•  Bone Marrow Stem 
cells significantly 
improved overall, 
consciousness in pvs, 
and motor function.  
•  Age and time to 
treatment should be 
further investigated as 
prognosis indicators.  
Treatment of severe 
TBI using bone 
marrow derived 
mononuclear stem 
cells. An open label, 
non-randomized, 
clinical trial. Cox et 
al.(2016) 
•  Sample Size:25 
•  4 treatment arms; low 
dose, moderate dose, 
high dose, and control 
(none). 
•  CT to assess changes in 
Global white matter 
volume, Supratentorial 
volume, Pulmonary 
Function-Murray score, 
biomarker analysis, and 
correlation between 
Callosal fibers and 
Neurobehavior 
outcomes.  
•  Well preserved 
supratentorial volume 
and white matter 
volume(P=.0294 & P=.
0049) at 6 month when 
compared with control. 
•  Dose variation not 
significant. 
•  Pulmonary Function-
Murray Scoring 
increased in treatment 
arm (P<.05) 
•  Potential observer bias. 
•  Small sample size 
•  Injury heterogeneity  
•  Gender disparity; more 
males in high dose. 
•  Decompressive 
Craniectomy and ventricular 
drain placement rate higher 
in treatment arms. 
•  Due to small sample size 
control and treated cases 
were pooled and thus left 
out of this analysis. 
•  No serious adverse 
effects or reactions. 
•  Functional outcomes 
correlate with brain 
tissue preservation. 
•  Evidence shows stem 
cells may exhibit 
neuroprotection, 
reducing inflammation 
and structural damage 
post TBI. 
Regenerating	Life:	Stem	Cell	Therapy	in	TBI														
	
17	
Discussion 
In the past it was thought that neurons were unable to regenerate or renew after injury. However 
evidence has shown the presence of stem cells with in the brain that are able to differentiate in to 
oligodendrocytes, astrocytes, and nerve cells. With this in mind, current treatments aim to reduce 
factors that lead to secondary TBI like hypoxia, hypotension, increased intracranial pressure, and 
hypoglycemia. However new research points to the possibility that stem cells can infiltrate the 
brain and encourage regeneration in patients’ existing neurons and stimulate new neurons to 
differentiate. This could lead to vast improvements in function, memory, physical abilities, and 
quality of life.  
 
In the clinical trial conducted by Wang et al. significant improvements with stem cell injections 
in neurocognitive function tests as well as motor scores were seen in almost every treatment 
group when compared with control. Cox et al. showed evidence of correlation between stem cell 
therapy and preservation of white matter within the brain and supratentorial volume. With less 
brain volume loss patients were able to preform at higher levels on neurocognitive function tests. 
The mechanism behind this is unknown and should be further investigated. Whether this 
correlation is due to stem cell therapy aiding in regeneration of neurons or instead it reducing 
neuroinflammation, decreasing loss of white matter remains to be seen. It is clear now that CT 
should be incorporated in to future clinical trials as a means of patient and treatment effect 
evaluation. All three of the studies reported at statistically significant improvements in at least 
two areas tested. They were also all limited by injury heterogeneity, low attrition rates, and either 
observer bias or patient bias. 
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Stem cell therapy could affect outcomes both in the acute setting and in the recovery process. It 
is thought that damage to neurons is a result of inflammation that leads to hypoxic conditions and 
cell death throughout the neuronal environment. If researchers can find a way to intervene in this 
process they could greatly reduce poor prognosis. The ability to regenerate neurons and stimulate 
self-renewal could slow and even eliminate the cascade of events primary brain injury sets in to 
motion.   
 
Many of the current interventions are aimed at treatment during the primary phase of injury 
however with the secondary phase lasting up to several months there is a great opportunity to 
affect long term outcomes during this time. Further research in reducing symptoms of TBI in the 
months and years after the initial insult should be conducted as there is limited evidence in this 
area. Wang et el. sought to do this by treating patients at least 1 year after initial injury. Results 
were promising with TBI-related sequelae significantly reduced in the treatment arm however 
due to multiple limitations of the study should be further investigated with a randomized, double 
blinded control trial. 
 
The current studies in stem cell implantation have followed many successful animal trials 
demonstrating promising outcomes for humans. The limitations placed on how stem cells can be 
collected and used stands as a major barrier to the advancement of stem cell research. New 
collection methods that pose little ethical issue could increase the number of clinical trials and 
become more widely accepted.  
 
Research involving cell differentiation and ways to direct stem cells to target tissues should be 
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conducted in order to increase efficacy of stem cell transplant to regenerate neuronal cells.  
Another drawback to stem cell therapy with MSC’s may be their suppression of patient’s 
antitumor response as Djouad et al. reported.2 Very few adverse effects have been seen in clinical 
trials to date but there is a possibility that with more research a link between increased tumors 
and stem cell therapy may be found. 
 
TBI’s can be reduced and lives can be saved with more attention to education surrounding fall 
risks, safety equipment, motor vehicle safety, etc. However, not all TBI’s can be prevented. 
Neuronal regeneration and renewal through stem cell treatment could allow scientists to prevent 
primary TBIs from causing secondary injuries that result in life long disabilities and eliminate 
debilitating sequelae. This could reduce the overall impact of their medical care costs to the 
healthcare system by billions of dollars each year and improve the lives of millions of TBI 
survivors around the world. 
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